Acetylcholinesterase (AChE) inhibitors are widely used for the symptomatic treatment of
Alzheimer's disease and other dementias. More recent use is for myasthenia gravis. Many of …

Background and objective Sugammadex has been introduced for reversal of rocuronium (or
vecuronium)–induced neuromuscular blockade (NMB). Although its efficacy has been …

These practice guidelines provide evidence-based recommendations on the management
of neuromuscular monitoring and antagonism of neuromuscular blocking agents during and …

Sugammadex is the first clinical representative of a new class of drugs called selective
relaxant binding agents. It has revolutionized the way anesthesiologists think about drug …

This article describes methods used to estimate parameters governing long-term survival, or
times to other events, for health economic models. Specifically, the focus is on methods that …

The cost-effectiveness of sugammadex for the routine reversal of muscle relaxation
produced by rocuronium or vecuronium in UK practice is uncertain. We performed a …

Abstract Objectives Neuromuscular blocking agents (NMBAs) have revolutionized the field
of anesthesiology as they facilitate airway management and ensure optimal surgical …

Study objective Sugammadex has been introduced for reversal of neuromuscular blockade
(NMB) induced by rocuronium (or vecuronium). Although its efficacy and safety have been …

Sugammadex 16 mg kg− 1 can be used for the immediate reversal of neuromuscular block 3
min after administration of rocuronium and could be used in place of succinylcholine for …

Background The beneficial effects of deep blockade are not fully known. In this study, we
evaluated the effect of deep neuromuscular blockade on surgical conditions during …